Aditxt Inc.

News & Events

Press Releases

In The Media

1. Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

   Business Wire JUN 9, 2025 8:15 AM EDT
   Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social i...
   READ ARTICLE

2. Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

   Business Wire JUN 5, 2025 8:15 AM EDT
   Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt”), a social innovation platform accelerating...
   READ ARTICLE

3. Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

   GlobeNewswire MAY 19, 2025 8:00 AM EDT
   NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
   READ ARTICLE

4. Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

   Business Wire MAY 19, 2025 8:00 AM EDT
   Will eliminate approximately $16M in closing obligations Aditxt, Inc. (NASDAQ: ADTX) ...
   READ ARTICLE

5. Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt(TM), and Dr. Friedrich Kapp, Co-CEO of Adimune(TM), to Discuss Progress of Lead Therapeutic Candidate ADI-100(TM)

   Business Wire MAY 2, 2025 9:00 AM EDT
   Event Begins Today at 11:30 a.m. ET Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "C...
   READ ARTICLE

6. KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

   Business Wire APR 17, 2025 9:08 PM EDT
   Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 &...
   READ ARTICLE

7. KILL Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)

   Business Wire APR 17, 2025 9:03 PM EDT
   Aditxt, Inc. requests that their press release NewsItemId: 20250417385764 “Dr. Charles How...
   READ ARTICLE

8. Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)

   Business Wire APR 17, 2025 8:15 AM EDT
   Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerat...
   READ ARTICLE

9. Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

   Business Wire APR 16, 2025 8:15 AM EDT
   Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic...
   READ ARTICLE

10. Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

    Business Wire APR 14, 2025 8:15 AM EDT
    Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune ...
    READ ARTICLE